Diagnostics & Diseases Market Research Reports & Industry Analysis

Diagnostics involves investigating and discovering certain diseases, conditions and injuries by closely studying various symptoms and indications displayed by patients. In broad terms, today’s Diagnostics Industry breaks down into the following categories, namely in-vitro diagnostics (IVD) (examination of diverse tissue samples in a laboratory) and in-vivo diagnostics (observation and testing of tissue and any organ’s functioning by exploiting the techniques like medical (diagnostic) imaging and monitoring).

A nearly EUR 37.5 billion sector, in-vitro diagnostics promises enormous growth potential, with governments increasingly redefining soaring healthcare spending and starting to pour investments into the high tech diagnostics business. The latter continues to be superintended by a mere scattering of behemoths. Major forces fuelling the industry development include, among others, innovative approaches regarding equipment and clinical trial activities.

This Catalogue presents an invaluable collection of research reports examining the Diagnostics and Diseases Market worldwide, by various regions and selected countries. The research reports feature market sizing analyses and growth rate reviews, discussions of factors diving or deterring the growth of the Diagnostics and Diseases Industry, information on market dynamics and share, etc. The profiles of large-to-micro caps, and the Diagnostics and Diseases Market forecasts are provided in the research reports too.

Found 5187 publications
Human Microbiome Market by Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder), Application (Therapeutic, Diagnostic) & by Product (Probiotic, Prebiotic, Food,... US$ 4,650.00

... and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side ... . The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats) and technological trends, ...

Sep, 2014 146 pages
US Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 4,000.00

This unique report from Venture Planning Group provides US sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R& ...

136 pages
UK Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 2,600.00

This unique report from Venture Planning Group provides UK sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in R& ...

124 pages
Spain Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 2,950.00

This unique report from Venture Planning Group provides Spain sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in ...

128 pages
Japan Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 3,000.00

This unique report from Venture Planning Group provides Japan sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in ...

129 pages
Italy Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 2,500.00

This unique report from Venture Planning Group provides Italy sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in ...

125 pages
Germany Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 2,950.00

This unique report from Venture Planning Group provides Germany sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

128 pages
France Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 3,200.00

This unique report from Venture Planning Group provides France sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

100 pages
Europe Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 6,000.00

This unique report from Venture Planning Group provides Europe sales and market share estimates for major suppliers of cancer diagnostic testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

151 pages
Sales and Market Shares of Major Cancer Diagnostic Testing Product Suppliers by Assay and Country US$ 9,200.00

This unique report from Venture Planning Group provides sales and market share estimates for major suppliers of cancer diagnostic testing ... presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

174 pages
Restenosis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 SUMMARY GlobalData's clinical trial report, “Restenosis Global Clinical Trials Review, H2, 2014' provides data on the Restenosis clinical trial scenario. This ... type and many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / ...

Sep, 2014 88 pages
Hot Flashes Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Hot Flashes. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 109 pages
Hematoma Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... SUMMARY GlobalData's clinical trial report, “Hematoma Global Clinical Trials Review, H2, 2014' provides data on the Hematoma clinical trial scenario. This ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 62 pages
Heart Valve Disease Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Heart Valve Disease clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 71 pages
Heart Attack Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Heart Attack. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Sep, 2014 78 pages
Giant Cell Arteritis Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... Trials Review, H2, 2014' provides data on the Giant Cell Arteritis clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Sep, 2014 70 pages
Endothelial Dysfunction Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Endothelial Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Sep, 2014 76 pages
Eisenmenger Syndrome Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Eisenmenger Syndrome. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Aug, 2014 81 pages
Edema Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... 2014 SUMMARY GlobalData's clinical trial report, “Edema Global Clinical Trials Review, H2, 2014' provides data on the Edema clinical trial scenario. This ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Aug, 2014 78 pages
Diastolic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Diastolic Hypertension. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Aug, 2014 70 pages
Diabetic Hypertension Global Clinical Trials Review, H2, 2014 US$ 2,500.00

... and data relating to the clinical trials on Diabetic Hypertension. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Aug, 2014 62 pages
EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023 US$ 3,995.00

EpiCast Report: Breast Cancer (HER2-, HER2+) - Epidemiology Forecast to 2023 SUMMARY Breast cancer is a malignant tumor that originates in the breast tissues. ... historical data obtained from the WHO International Agency for Cancer Research’s (IARC’s) SurvCan, the Surveillance of Epidemiology and End Results ...

Sep, 2014 70 pages
Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Zontivity (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... initiates a strong platelet-activating, pro-thrombotic, signal transduction pathway. Zontivity locks the PAR1 receptor into a conformation that prevents thrombin ...

Jul, 2014 88 pages
Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Xarelto (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... and fundamentally alter the ACS market, both medically and financially. Xarelto was approved in the EU for the prevention of non-valvular atrial ...

Jul, 2014 91 pages
PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for the 7MM ... ACS market, both medically and financially. Of the 7MM forecast for acute coronary syndrome, the US market dominates the other six countries in sales for ...

Jul, 2014 233 pages
PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 US$ 4,995.00

PharmaPoint: Acute Coronary Syndrome - Japan Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for ... impact of key events as well the drivers and restraints affecting the Japan ACS market. REASONS TO BUY Understand and capitalize by identifying products ...

Jul, 2014 218 pages
PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 US$ 6,995.00

PharmaPoint: Acute Coronary Syndrome - 5EU Drug Forecast and Market Analysis to 2023 SUMMARY GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded drug sales (40%) and $7.3bn in generic sales (60%). GlobalData expects that the ACS drug ...

Jul, 2014 277 pages
Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Evolocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... increases the body’s ability to filter LDL-C from the circulation. Evolocumab is one of several PCSK9 inhibitors navigating critical Phase III clinical ...

Jul, 2014 90 pages
Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly ...

Jul, 2014 86 pages
Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Effient (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... of P2Y12 blocks key signaling events in platelets that lead to coagulation. Effient is supplied as 10mg tablets and is administered as a 60mg loading dose during ...

Jul, 2014 60 pages
Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Crestor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... . It is the most potent of all of the HMG-CoA reductase inhibitors. Crestor faces steep competition from the generic statins, especially atorvastatin, ...

Jul, 2014 60 pages
Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Cangrelor (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... 2012 agreement, The Medicines Company will not have marketing rights to cangrelor in Japan. GlobalData assumes, for this forecast, that AstraZeneca will ...

Jul, 2014 88 pages
Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Brilinta (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... for use in the US under the brand name Brilinta (AstraZeneca, press release, July 20, 2011). Brilinta is indicated for use in patients during the ...

Jul, 2014 59 pages
Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... medically and financially. GlobalData anticipates that Pfizer’s PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgen ...

Jul, 2014 85 pages
Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... Coronary Syndrome) - Forecast and Market Analysis to 2023 SUMMARY GlobalData has released its new PharmaPoint Drug Evaluation report, “Angiomax (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS market - primarily comprised of antithrombotics, antihypertensives, and statins ...

Jul, 2014 59 pages
Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... has released its new PharmaPoint Drug Evaluation report, “Anacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ... (Determining the Efficacy and Tolerability of Cholesteryl Ester Transfer Protein [CETP] Inhibition with Anacetrapib) Phase III study demonstrated the ability ...

Jul, 2014 88 pages
Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023 US$ 3,495.00

... GlobalData has released its new PharmaPoint Drug Evaluation report, “Alirocumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023”. The current ACS ... flush with new mAbs. In its current state, GlobalData expects that alirocumab will be the second-to-market PCSK9, following Amgen’s PCSK9 mAb, ...

Jul, 2014 91 pages
2014 World In Vitro Diagnostics Industry: Market Shares and Country Forecasts for 400 Assays, 20 Market Segments and 14 Test Locations--Emerging Opportunities and Business Expansion... US$ 175,000.00

... Group has published a series of 10 global market research surveys, “2014 World In Vitro Diagnostics Industry: Market Shares and Country Forecasts.” The ... , Japan, Spain, UK, USA Sales Forecasts, Supplier Shares, Competitive Strategies 2014 Molecular Blood Typing, Grouping and Infectious Disease NAT Market: ...

Aug, 2014 9700 pages
US Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 6,500.00

This unique report from Venture Planning Group provides Europe sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 200 pages
UK Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 3,200.00

This unique report from Venture Planning Group provides UK sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products in ...

Sep, 2014 108 pages
Spain Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 4,600.00

This unique report from Venture Planning Group provides Spain sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 114 pages
Japan Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 4,750.00

This unique report from Venture Planning Group provides Japan sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 115 pages
Italy Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 4,500.00

This unique report from Venture Planning Group provides Italy sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 113 pages
Germany Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 4,650.00

This unique report from Venture Planning Group provides Germany sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 115 pages
France Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 4,850.00

This unique report from Venture Planning Group provides France sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 118 pages
Europe Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 10,800.00

This unique report from Venture Planning Group provides Europe sales and market share estimates for major suppliers of infectious disease testing ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 200 pages
Sales and Market Shares of Major Infectious Disease Testing Product Suppliers by Assay and Country US$ 14,500.00

This unique report from Venture Planning Group provides sales and market share estimates for major suppliers of infectious disease testing ... presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 260 pages
Europe Sales and Market Shares of Major Blood Typing, Grouping and Infectious Disease Screening Product Suppliers by Test and Country US$ 5,450.00

This unique report from Venture Planning Group provides Europe sales and market share estimates for major suppliers of blood typing, grouping and ... strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 104 pages
US Sales and Market Shares of Major Blood Typing, Grouping and Infectious Disease Screening Product Suppliers by Test US$ 2,950.00

This unique report from Venture Planning Group provides US sales and market share estimates for major suppliers of blood typing, grouping ... presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014 87 pages
UK Sales and Market Shares of Major Blood Typing, Grouping and Infectious Disease Screening Product Suppliers by Test US$ 2,500.00

This unique report from Venture Planning Group provides UK sales and market share estimates for major suppliers of blood typing, grouping ... presents strategic assessments of major suppliers and emerging market entrants, including their product portfolios, marketing tactics, technological know-how, new products ...

Sep, 2014
1 2 3 4 5 >
Skip to top